<DOC>
	<DOCNO>NCT00098683</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , amifostine , work different way stop growth cancer cell , either kill cell stop dividing . PURPOSE : This phase II trial study well amifostine work treat young patient newly diagnose de novo myelodysplastic syndrome .</brief_summary>
	<brief_title>Amifostine Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine hematologic effect amifostine , term , complete partial response , pediatric patient newly diagnose de novo myelodysplastic syndrome ( MDS ) . - Determine safety efficacy drug patient . Secondary - Determine efficacy drug prevent conversion MDS acute myeloid leukemia ( AML ) term proportion patient remain free AML completion study treatment . - Determine duration progression-free remission MDS conversion AML patient treat drug . - Determine effect karyotypic abnormality survival duration diagnosis MDS conversion AML patient treat drug . - Determine effect bone marrow blast count survival duration diagnosis MDS conversion AML patient treat drug . - Determine effect number cytopenia survival patient treat drug . - Correlate duration time diagnosis MDS conversion AML survival patient treated drug . OUTLINE : This multicenter study . Patients receive amifostine IV 1-3 minute day 1 , 3 , 5 , 8 , 10 , 12 , 15 , 17 , 19 . Treatment repeat every 5 week 2 course absence disease progression unacceptable toxicity . Patients stable respond disease planning undergo match donor bone marrow cord blood transplantation continue therapy transplantation . Patients stable respond disease undergoing transplantation may receive 4 additional course amifostine absence disease progression unacceptable toxicity . Following completion therapy amifostine , patient follow monthly 1 year , every 2 month 1 year , every 3 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 10-20 patient accrue study within 5-10 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis myelodysplastic syndrome ( MDS ) One follow subtypes : Refractory anemia ( RA ) RA ring sideroblast RA excess blast Refractory cytopenia multilineage dysplasia ( RCMD ) RCMD ring sideroblast MDS , unclassified MDS associate isolated del 5 ( q ) De novo disease No treatmentinduced MDS No juvenile myelomonocytic leukemia No Down syndrome , Fanconi 's anemia , inherit form hypoplastic bone marrow failure PATIENT CHARACTERISTICS : Age 1 21 original diagnosis Performance status Karnofsky 50100 % ( patient &gt; 16 year age ) Lansky 50100 % ( patient 1 16 year age ) Life expectancy At least 8 week Hematopoietic See Disease Characteristics Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT &lt; 2.5 time ULN Renal Radioisotope glomerular filtration rate ≥ 60 mL/min OR Creatinine clearance &gt; 60 mL/min ( base Schwartz formula ) Calcium normal Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Serum electrolytes normal Phosphorus normal Magnesium normal Glucose normal No concurrent malignancy PRIOR CONCURRENT THERAPY : Biologic therapy More 8 week since prior growth factor No concurrent growth factor No concurrent hematopoietic stem cell transplantation No concurrent immunomodulating agent Chemotherapy No prior amifostine No concurrent anticancer chemotherapy Endocrine therapy No concurrent daily steroid therapy Radiotherapy Not specify Surgery Not specify Other No prior therapy MDS</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
</DOC>